Prostate Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Advaxis, Inc., Tracon Pharmaceuticals Inc., Bristol-Myers

DelveInsight's "Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Prostate Cancer, historical and forecasted epidemiology as well as the Prostate Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the Prostate Cancer Market Share @ Prostate Cancer Market Outlook- https://www.delveinsight.com/sample-request/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Prostate Cancer Market Report
• In March 2025, Curium US LLC announced a study will include a group of 26 patients with metastatic prostate cancer. Each patient will be administered a 7-9 mCi intravenous dose of copper Cu 64 PSMA I&T injection. PET/CT images will be acquired for all patients at 1 hour ± 15 minutes and 4 hours ± 30 minutes post copper Cu 64 PSMA I&T injection.
• In March 2025, Janssen Research & Development, LLC announced a study is to determine if newly diagnosed (within previous 3 months) participants with metastatic (spread of cancer cells from one part of the body to another ) hormone-naive prostate cancer (mHNPC) who have high-risk prognostic factors will benefit from the addition of abiraterone acetate plus low-dose prednisone to androgen deprivation therapy (ADT; lutenizing hormone releasing hormone [LHRH] agonists or surgical castration).
• In March 2025, Novartis Pharmaceuticals announced a study is to evaluate the efficacy and safety of AAA617 alone (Lutetium [177Lu] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in participants with PSMA-positive, castration-resistant prostate cancer and no evidence of metastasis in conventional imaging (CI) (i.e., CT/MRI and bone scans). Approximately 120 participants will be randomized.
• In 2023, the 7MM had approximately 7,279,500 prevalent cases of prostate cancer. These are expected to rise due to the growing geriatric population and advancements in diagnostic capabilities during the forecast period (2024-2034).
• The five-year prevalent cases of prostate cancer in the US was ~1,093,300 in 2023.
• Among the EU4 and the UK, Germany accounted for the highest number of metastatic CRPC cases while, Spain had the lowest cases, in 2023.
• As per the estimates, in the US, majority of the cases were found to be localized/locally advanced cases (Stage I-III), comprising approximately 56% of total cases, while nearly 33% belonged to biochemical recurrence/ progressive cases, and ~11% belonged to metastatic cases.
• Around 43% of all metastatic prostate cancer cases are attributed for mCRPC and rest 57% are attributed for mCSPC.
• The increase in Prostate Cancer Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Prostate Cancer Market is anticipated to witness growth at a considerable CAGR.
• The leading Prostate Cancer Companies such as Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Advaxis, Inc., Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Regeneron Pharmaceuticals, Veru Inc., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., Janux Therapeutics, Fusion Pharmaceuticals, Corbus Pharmaceuticals, BioXcel Therapeutics, Onxeo S.A, Ayala Pharmaceuticals, HOOKIPA Pharma, Nuvation Bio, Ambrx, enGene, Jemincare, CellVax Therapeutics, POINT Biopharma, Oncternal Therapeutics, Immunic AG, BioNTech SE, and others.
• Promising Prostate Cancer Pipeline Therapies such as Abiraterone with Prednisone or Enzalutamide, 64Cu-PSMA I&T, Apalutamide, Abiraterone acetate, Prednisone and others.

Stay ahead in the Prostate Cancer Therapeutics Market with DelveInsight's Strategic Report @ Prostate Cancer Market Outlook- https://www.delveinsight.com/sample-request/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Prostate Cancer Epidemiology Segmentation in the 7MM
The prostate cancer epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent cases of Prostate cancer, Five-year Prevalent cases of Prostate cancer, Age-specific cases of Prostate cancer, and Total cases of Prostate cancer by clinical stages (Total Prevalent cases of nmCSPC, Total Prevalent cases of mCSPC, Total Prevalent cases of nmCRPC, and Total Prevalent cases of mCRPC) in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2020 to 2034.

Download the report to understand which factors are driving Prostate Cancer Epidemiology trends @ Prostate Cancer Prevalence- https://www.delveinsight.com/sample-request/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Prostate Cancer Marketed Drugs
• NUBEQA (darolutamide): Bayer
NUBEQA (darolutamide) is an oral androgen receptor inhibitor. It is indicated for the treatment of adult patients with nmCRPC and mCSPC/mHSPC in combination with docetaxel. NUBEQA is administered 600 mg, (two 300 mg tablets) orally twice daily. In 2023, Bayer reported that its global revenue from NUBEQA amounted to around USD 941 million.

• ERLEADA (apalutamide): Johnson & Johnson Innovative Medicine (Janssen)
ERLEADA is a next-generation oral androgen receptor inhibitor. It is indicated for the treatment of patients with mCSPC/mHSPC and nmCRPC. ERLEADA is administered 240 mg orally once daily. In 2023, Johnson & Johnson Innovative Medicine reported that its global revenue from ERLEADA amounted to USD 2,387 million.

• XTANDI (enzalutamide): Astellas Pharma/Pfizer
XTANDI is an orally bioavailable, organic, non-steroidal small molecule targeting the AR with potential antineoplastic activity. It is indicated for the treatment of patients with CRPC, mCSPC/mHSPC, nmCRPC with biochemical recurrence at high risk for metastasis. XTANDI is administered 160 mg orally once daily. In 2023, Pfizer reported that its global revenue from XTANDI amounted to USD 1,191 million

Prostate Cancer Emerging Drugs
• Opevesostat (MK-5684; ODM-208): Merck and Orion
Opevesostat is an oral, non-steroidal, and selective inhibitor of CYP11A1 discovered and developed by Orion and is being investigated for the treatment of hormone-dependent cancers, such as prostate cancer. In July 2024, Merck and Orion announced a mutual exercise of options providing Merck global exclusive rights to opevesostat for the treatment of mCRPC. Merck and Orion initiated OMAHA1 (NCT06136624) and OMAHA2a (NCT06136650), two pivotal Phase III clinical trials evaluating opevesostat in combination with hormone replacement therapy (HRT), for the treatment of certain patients with mCRPC. Final results from the OMAHA1 trial are expected in 2028 and OMAHA2a trial final results are anticipated in 2030. In addition to these, Merck has also presented updated CYPIDES Phase II results of opevesostat mCRPC at ESMO Congress 2024.

• CAN-2409: Candel Therapeutics
CAN-2409, Candel's most advanced viral immunotherapy candidate, is a replication-defective adenovirus that delivers the herpes simplex virus thymidine kinase (HSV-tk) gene to cancer cells. Moreover, according to the company's corporate presentation, the company expects to announce topline data from this clinical trial by Q4 2024 for its ongoing placebo-controlled, randomized pivotal Phase III clinical trial of CAN-2409 in patients with low-to-intermediate-risk, localized, non-metastatic-prostate-cancer-and-Phase-II-trial-for-patients-undergoing active surveillance for localized prostate cancer. The drug CAN-2409 is presently undergoing evaluation in a Phase I clinical trial to assess its safety and tolerability in patients.

• KPG-121: Kangpu Biopharmaceuticals
KPG-121 is a modulator of the Cereblon (CRBN) E3 ubiquitin ligase complex CRL4-CRBN targeting rapid ubiquitination and degradation of casein kinase 1A1 (CK1a) and transcription factors Aiolos (IKZF3) and Ikaros (IKZF1). KPG-121 promotes anti-proliferation and anti-angiogenesis activities and enhances immunomodulatory properties. A Phase I study to evaluate the safety, pharmacokinetics, and efficacy of KPG-121 when combined with enzalutamide, abiraterone, or apalutamide for the treatment of patients with mCRPC or nmCRPC was completed in the US. KPG-121 was well tolerated and demonstrated a favorable pharmacokinetic profile as well as promising efficacy.

To learn more about Prostate Cancer treatment guidelines, visit @ Prostate Cancer Treatment Market Landscape- https://www.delveinsight.com/sample-request/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Prostate Cancer Market Outlook
Prostate cancer starts as localized prostate cancer when only found in the prostate and surgery or radiation can be used to treat it. Sometimes, hormone therapy might also be used. Increased sophistication of prostate imaging has allowed for the rapid emergence of focal therapies such as focal laser ablation, high-intensity focal ultrasound (HIFU), irreversible electroporation (IRE), photodynamic therapy (VTP), and focal cryotherapy. Radical prostatectomy can be open (ORP), laparoscopic (LRP), or robotic-assisted (RARP). ORP is the traditional method, whilst LRP and RARP are increasing in popularity.

Prostate Cancer Drugs Market
Currently, the market holds a diverse range of therapeutic alternatives for treatment, including PARP inhibitors, androgen receptor inhibitors, CYP17 inhibitors, microtubule inhibitors, radioligand therapies, GnRH receptor antagonists, and others in different lines of treatment. Androgen receptor pathway inhibitors are a mainstay of treatment for patients with prostate cancer. There are currently four approved androgen receptor pathway inhibitors in the United States: three anti-androgens - apalutamide, enzalutamide, and darolutamide, as well as an androgen receptor pathway inhibitor, abiraterone acetate.

Major Prostate Cancer Companies
Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Advaxis, Inc., Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Regeneron Pharmaceuticals, Veru Inc., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., Janux Therapeutics, Fusion Pharmaceuticals, Corbus Pharmaceuticals, BioXcel Therapeutics, Onxeo S.A, Ayala Pharmaceuticals, HOOKIPA Pharma, Nuvation Bio, Ambrx, enGene, Jemincare, CellVax Therapeutics, POINT Biopharma, Oncternal Therapeutics, Immunic AG, BioNTech SE, and others.

Learn more about the FDA-approved drugs for Prostate Cancer @ Drugs for Prostate Cancer Treatment- https://www.delveinsight.com/sample-request/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Prostate Cancer Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Prostate Cancer Companies- Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Advaxis, Inc., Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc, Arvinas Inc, Epizyme, Regeneron Pharmaceuticals, Veru Inc., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., Janux Therapeutics, Fusion Pharmaceuticals, Corbus Pharmaceuticals, BioXcel Therapeutics, Onxeo S.A, Ayala Pharmaceuticals, HOOKIPA Pharma, Nuvation Bio, Ambrx, enGene, Jemincare, CellVax Therapeutics, POINT Biopharma, Oncternal Therapeutics, Immunic AG, BioNTech SE, and others.
• Prostate Cancer Pipeline Therapies- Abiraterone with Prednisone or Enzalutamide, 64Cu-PSMA I&T, Apalutamide, Abiraterone acetate, Prednisone and others.
• Prostate Cancer Market Dynamics: Prostate Cancer Market Drivers and Barriers
• Prostate Cancer Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Prostate Cancer Drugs in development @ Prostate Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Prostate Cancer Executive Summary
3. Prostate Cancer Competitive Intelligence Analysis
4. Prostate Cancer: Market Overview at a Glance
5. Prostate Cancer: Disease Background and Overview
6. Patient Journey
7. Prostate Cancer Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Prostate Cancer Unmet Needs
10. Key Endpoints of Prostate Cancer Treatment
11. Prostate Cancer Marketed Products
12. Prostate Cancer Emerging Therapies
13. Prostate Cancer: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Prostate Cancer Market Outlook
16. Access and Reimbursement Overview of Prostate Cancer
17. KOL Views
18. Prostate Cancer Market Drivers
19. Prostate Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Top Selling Market Research Reports in 2025

Autosomal Dominant Polycystic Kidney Disease Market- https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-market
Familial Lipoprotein Lipase Deficiency Pipeline- https://www.delveinsight.com/report-store/familial-lipoprotein-lipase-deficiency-pipeline-insight
Frontotemporal Dementia Pipeline- https://www.delveinsight.com/report-store/frontotemporal-dementia-pipeline-insight
Human Papillomavirus-positive Oropharyngeal Cancer Market- https://www.delveinsight.com/report-store/human-papillomavirus-positive-oropharyngeal-cancer-market
Moderate And Severe Chronic Kidney Disease Market- https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market
Monoclonal Gammopathy Of Undetermined Significance Market- https://www.delveinsight.com/report-store/monoclonal-gammopathy-of-undetermined-significance-market
Myopia Treatment Devices Market- https://www.delveinsight.com/report-store/myopia-treatment-devices-market
Myotonic Dystrophy Market- https://www.delveinsight.com/report-store/myotonic-dystrophy-market
Neurodermatitis Market- https://www.delveinsight.com/report-store/neurodermatitis-market
Osteochondrodysplasia Market- https://www.delveinsight.com/report-store/osteochondrodysplasia-market
Peptic Ulcer Hemorrhage Market- https://www.delveinsight.com/report-store/peptic-ulcer-hemorrhage-market
Perivascular Epithelioid Cell Tumor Market- https://www.delveinsight.com/report-store/perivascular-epithelioid-cell-tumor-market
Plasmodium Vivax Malaria Market- https://www.delveinsight.com/report-store/plasmodium-vivax-malaria-market
Thymidine Kinase 2 Deficiency Market- https://www.delveinsight.com/report-store/thymidine-kinase-2-deficiency-tk2d-market
Xlinked Severe Combined Immunodeficiency Market- https://www.delveinsight.com/report-store/xlinked-severe-combined-immunodeficiency-scid-market
Chagas Disease Market - https://www.delveinsight.com/report-store/chagas-disease-market
Diabetes Insipidus Market- https://www.delveinsight.com/report-store/diabetes-insipidus-market
Geographic Atrophy Market- https://www.delveinsight.com/report-store/geographic-atrophy-ga-market
Peanut Allergy Market Report- https://www.delveinsight.com/report-store/peanut-allergy-market
Postherpetic Neuralgia Market- https://www.delveinsight.com/report-store/postherpetic-neuralgia-market
Pouchitis Market- https://www.delveinsight.com/report-store/pouchitis-market
Presbyopia Market- https://www.delveinsight.com/report-store/presbyopia-market
Prostate Cancer Market- https://www.delveinsight.com/report-store/prostate-cancer-market-insight
Refractory Metastatic Melanoma Market- https://www.delveinsight.com/report-store/refractory-metastatic-melanoma-market
Rubella Market- https://www.delveinsight.com/report-store/rubella-market
Smoking Cessation And Nicotine Addiction Market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
Systemic Inflammatory Response Syndrome Market- https://www.delveinsight.com/report-store/systemic-inflammatory-response-syndrome-market
Systemic Inflammatory Response Syndrome Market Insights- https://www.delveinsight.com/report-store/systemic-inflammatory-response-syndrome-market
Uveal Melanoma Market- https://www.delveinsight.com/report-store/ocular-melanoma-market
Wiskott-aldrich Syndrome Market- https://www.delveinsight.com/report-store/wiskott-aldrich-syndrome-market
Adult T-cell Leukemia-lymphoma Market- https://www.delveinsight.com/report-store/adult-t-cell-leukemia-lymphoma-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Asperger Syndrome Market- https://www.delveinsight.com/report-store/asperger-syndrome-market
House Dust Mite Allergy Market- https://www.delveinsight.com/report-store/house-dust-mite-allergy-market
Immune Thrombocytopenia Market- https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market
Keloid Market- https://www.delveinsight.com/report-store/keloid-market
Pcsk9 Market- https://www.delveinsight.com/report-store/pcsk9-inhibitors-psck9i-market
Peripheral Nerve Repair Devices Market- https://www.delveinsight.com/report-store/peripheral-nerve-repair-devices-market
Sarcopenia Market- https://www.delveinsight.com/report-store/sarcopenia-market
Skin Neoplasm Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Vascular Imaging Devices Market- https://www.delveinsight.com/report-store/vascular-imaging-market-market
Venous Ulcer Market- https://www.delveinsight.com/report-store/venous-leg-ulcer-market
Cardiogenic Shock Market- https://www.delveinsight.com/report-store/cardiogenic-shock-market
Herpes Labialis Market- https://www.delveinsight.com/report-store/herpes-labialis-market
Meningococcal Meningitis Market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
Septic Shock Market- https://www.delveinsight.com/report-store/septic-shock-market
Transmucosal Drug Delivery Devices Market- https://www.delveinsight.com/report-store/transmucosal-drug-delivery-devices-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
Cone Rod Dystrophy Market- https://www.delveinsight.com/report-store/cone-rod-dystrophy-market
Orthopedic Power Devices Market- https://www.delveinsight.com/report-store/orthopedic-power-devices-market
Tendonitis Market- https://www.delveinsight.com/report-store/tendonitis-market
Diabetic Retinopathy Market- https://www.delveinsight.com/report-store/diabetic-retinopathy-market
Hydrocephalus Treatment Market- https://www.delveinsight.com/report-store/hydrocephalus-market
Short Bowel Syndrome Drug Market- https://www.delveinsight.com/report-store/short-bowel-syndrome-market
Spinal Trauma Devices Market- https://www.delveinsight.com/report-store/spinal-trauma-devices-market-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Tcr Therapy Market- https://www.delveinsight.com/report-store/tcr-therapy-market
Heart Failure Market- https://www.delveinsight.com/report-store/congestive-heart-failure-market
Surgical Robotic System Market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Thyroid Cancer Market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Indwelling Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.